Autoimmune diseases induced by TNF-targeted therapies

Best Practice and Research: Clinical Rheumatology

Volumn 22, Issue 5, 2008, Pages 847-861

  Ramos Casals, Manuel ^a   Brito Zerón, Pilar ^a   Soto, Maria Jose ^a   Cuadrado, Maria Jose ^b   Khamashta, Munther A ^b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

adalimumab; anti TNF; etanercept; infliximab; interstitial lung disease; lupus; thrombosis; vasculitis

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANKYLOSING SPONDYLITIS; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; CLINICAL FEATURE; CROHN DISEASE; DISEASE ASSOCIATION; EYE DISEASE; FOLLOW UP; HUMAN; INTERSTITIAL LUNG DISEASE; JUVENILE RHEUMATOID ARTHRITIS; LUPUS LIKE SYNDROME; MEDLINE; MIXED CONNECTIVE TISSUE DISEASE; MYOSITIS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SARCOIDOSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; UVEITIS; VASCULITIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; HUMANS; LUNG DISEASES, INTERSTITIAL; LUPUS ERYTHEMATOSUS, SYSTEMIC; MEDLINE; TUMOR NECROSIS FACTOR-ALPHA; VASCULITIS, ALLERGIC CUTANEOUS;

EID: 56349156989     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2008.09.008     Document Type: Review

References (30)

1. Haraoui B. Differentiating the efficacy of the tumor necrosis factor inhibitors. Seminars in Arthritis and Rheumatism 34 (2005) 7-11
2. Nurmohamed M.T., and Dijkmans B.A. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs 65 (2005) 661-694
3. Bongartz T., Sutton A.J., Sweeting M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA: The Journal of the American Medical Association 295 (2006) 2275-2285
4. Genovese M.C., Bathon J.M., Fleischmann R.M., et al. Long-term safety, efficacy and radiographic outcomes with etanercept treatment in patients with early rheumatoid arthritis. The Journal of Rheumatology 32 (2005) 1232-1242
5. Lebwohl M., Gottlieb A., Wallis W., and Zitnik R. Safety and efficacy of over 7 years of etanercept therapy in a global population of patients with rheumatoid arthritis. Journal of the American Academy of Dermatology 52 (2005) 195
6. Haraoui B., and Keystone E. Musculoskeletal manifestations and autoimmune diseases related to new biologic agents. Current Opinion in Rheumatology 18 (2006) 96-100
7. Rubin R.L. Drug-induced lupus. Toxicology 209 (2005) 135-147
8. Ramos-Casals M., Brito-Zerón P., Muñoz S., et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86 (2007) 242-251
9. Ali Y., and Shah S. Infliximab-induced systemic lupus erythematosus. Annals of Internal Medicine 137 (2002) 625-626
10. Eriksson C., Engstrand S., Sundqvist K.G., and Rantapaa-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Annals of the Rheumatic Diseases 64 (2005) 403-407
11. Charles P.J., Smeenk R.J., De Jong J., et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis and Rheumatism 43 (2000) 2383-2390
12. Cairns A.P., Duncan M.K., Hinder A.E., and Taggart A.J. New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Annals of the Rheumatic Diseases 61 (2002) 1031-1032
13. Favalli E.G., Sinigaglia L., Varenna M., and Arnoldi C. Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus 11 (2002) 753-755
14. Merkel P.A. Drug-induced vasculitis. Rheumatic Diseases Clinics of North America 27 (2001) 849-862
15. Gonzalez-Gay M.A., Garcia-Porrua C., and Pujol R.M. Clinical approach to cutaneous vasculitis. Current Opinion in Rheumatology 17 (2005) 56-61
16. Ramos-Casals M., Nardi N., Lagrutta M., et al. Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients. Medicine (Baltimore) 85 (2006) 95-104
17. Jennette J.C., Falk R.J., Andrassy K., et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis and Rheumatism 37 (1994) 187-192
18. Maini R.N., Breedveld F.C., Kalden J.R., et al., Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis and Rheumatism 50 (2004) 1051-1065
19. Merkel P.A., Lo G.H., Holbrook J.T., et al. Wegener's Granulomatosis Etanercept Trial Research Group. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of thrombosis (WeCLOT) Study. Annals of Internal Medicine 142 (2005) 620-626
20. Grinblat B., and Scheinberg M. The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review. Seminars in Arthritis and Rheumatism 37 (2008) 251-255
21. Kroesen S., Widmer A.F., Tyndall A., and Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology 42 (2003) 617-621
22. Bieber J., and Kavanaugh A. Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments. Rheumatic Diseases Clinics of North America 30 (2004) 257-270
23. Mohan N., Edwards E.T., Cupps T.R., et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis and Rheumatism 44 (2001) 2862-2869
24. Wolfe F., and Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis and Rheumatism 50 (2004) 1740-1751
25. Andrés E., Limbach F.X., Goichot B., and Sibilia J. Silent thyroiditis associated with etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases 61 (2002) 565
26. Schiff M.H., Burmester G.R., Kent J.D., et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 65 (2006) 889-894
27. Shakoor N., Michalska M., Harris C.A., and Block J.A. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359 (2002) 579-580
28. Flendrie M., Vissers W.H., Creemers M.C., et al. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Research & Therapy 7 (2005) R666-R676
29. Braun J., Baraliakos X., Listing J., and Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis and Rheumatism 52 (2005) 2447-2451
30. Puéchal X., Miceli-Richard C., Mejjad O., et al., Club Rhumatismes et Inflammation (CRI). Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis. Annals of the Rheumatic Diseases 67 (2008) 880-884